Immunovant Inc annual operating income for fiscal TTM was -$559 million, a decrease of 4.9% from -$533 million in fiscal 2026. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-12-31 | 2018-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | ($559M) | ($533M) | ($438M) | ($270M) | ($208M) | ($156M) | ($108M) | ($60M) | $0M | $0M | ($137M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | ($153M) | ($160M) | ($114M) | ($132M) | ($127M) | ($114M) | ($114M) | ($116M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More IMVT metrics: Revenue · Gross Profit · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All IMVT financial statements → Interactive IMVT charts →
About TickerBase · Data methodology & sources · Privacy · Terms